Wêrom de measte medyske ûndersiken troch de yndustry sels finansierd wurde
December 17, 2025 · Frisian News
Pharmaceutical and medical device companies now fund the majority of clinical research in wealthy nations, creating conflicts of interest that shape which treatments get studied and promoted. Independent funding for medical research has collapsed as governments cut budgets and universities turn to industry partnerships.
FryskIn ûndersiker oan in grutte universiteit publisearret resultaten dy't oantoane dat in nij hertmedisyn better wurket as besteande genêsmiddels. De finansieringsrigel ûnderoan it artikel iepenbierret de boarne: it bedriuw dat it nije genêsmiddel makket, betelle it hiele ûndersyk. Dit senario is no normaal yn medyske wittenskip. Farmaseutyske bedriuwen en medyske fabrikanten betelje no sawat 60 prosint fan alle klinyske ûndersiken yn de Feriene Steaten, en de sifers binne fergelykber yn oare wolfearjende lannen. Universiteiten en unôfhinklike ûndersyksynstituten, útput fan iepenbier jild, binne ôfhinklik wurden fan bedriuwskassen.
It probleem giet djipper as ienfâldige foaroardielen. As in bedriuw ûndersyk nei syn eigen produkt finansieret, kiest it de ûndersikers, stelt it de ûndersyksfraach en kontrôlearret it faak wat publisearre wurdt. Negatyfe resultaten oer it genêsmiddel fan it bedriuw komme selden oan it ljocht. In stúdzje út 2022 yn JAMA fûn dat ûndersiken finansierd troch farmaseutyske bedriuwen gunstige útkomsten trije kear faker rapportearden as unôfhinklik finansierde ûndersiken dy't deselde genêsmiddels teste. It effekt is echt en mjitber. Artsen en pasjinten lêze dizze publisearre resultaten en nimme behannellingsbeslissingen op basis fan unfolsleine ynformaasje.
Oerheidsmiddels foar fûneminteel medysk ûndersyk binne twa desennia lang lyk bleaun yn de measte wolfearjende lannen. It budzjet fan de National Institutes of Health, korrizjearre foar ynflaasje, is no lytser as yn 2003. Universiteiten reagearden troch har eigen ûndersyksbegrutting yn te krimpjen en swier te steunje op yndustriële partnerskippen. In professor dy't in ûndersyk útfiere wol, hat no faak bedriuwssponsoring nedich om de kosten te dekken. Dit jout farmaseutyske bedriuwen enoarme macht oer hokker sykten ûndersocht wurde, hokker behannellings ferlike wurde en hokker bywurkingen ûnder de oandacht brocht wurde. Ûndersyk nei goedkeape generyske genêsmiddels of previnsjestrategyen? Bedriuwen sille dit net finansierje. Ûndersyk nei djoere nije pillen? Se finansierje it royaal.
De partijdigens giet fierder as de sifers. Bedriuwen ûntwerpe ûndersiken om har genêsmiddels der goed útkomme te litten. Se stelle har medisinen tsjin plasebo's yn stee fan tsjin konkurrearjende behannellings. Se kieze pasjintepopulaasjes dy't it meast wierskynlik baat hawwe. Se mjitte útkomsten dy't har produkt begunstichje. Regulearders witte dat dit bart, en dochs fertrouwe hja hast folslein op troch de yndustry finansierde ûndersiken om te beslissen oft se nije genêsmiddels goedkarje. De foks beweakt it hok, en elkenien docht as of dit normaal is.
Guon lannen hawwe besocht de sirkel te brekken. De Britske National Health Service finansieret har eigen ûndersyksnetwurk. Dútslân en Skandinavje hawwe in sterkere iepenbiere ûndersyksbegrutting. Mar dit bliuwe útsûnderingen. Yn de Feriene Steaten en in grut diel fan de Ingelsksprekende wrâld fiert de farmaseutyske yndustry no medyske wittenskip út. Artsen oefenje genêskunde út op basis fan ûndersyk dat hja net finansierd en net ûntworpen hawwe. Pasjinten nimme genêsmiddels dêr't de goedkarring fan basearre is op bewiis dat troch bedriuwsbelangen foarmjûn is. It systeem wurket goed foar bedriuwen. Foar elkenien oars bliuwt de fraach net beantwordet: wat soene wy leare as wy dizze genêsmiddels werklik unôfhinklik ûndersochten?
A researcher at a major university publishes results showing a new heart medication works better than existing drugs. The funding line at the bottom of the paper reveals the source: the company that makes the new drug paid for the entire study. This scenario has become normal in medical science. Pharmaceutical firms and medical device makers now fund roughly 60 percent of all clinical research in the United States, and the numbers run similar in other wealthy countries. Universities and independent research institutes, starved of public money, have become dependent on corporate cash.
The problem runs deeper than simple bias. When a company funds research into its own product, it chooses the researchers, sets the research question, and often controls what gets published. Negative results about the company's drug rarely see the light of day. A 2022 study in JAMA found that trials funded by pharmaceutical firms reported favorable outcomes three times more often than independently funded trials testing the same drugs. The effect is real and measurable. Doctors and patients read these published results and make treatment decisions based on incomplete information.
Government funding for basic medical research has flatlined for two decades in most wealthy nations. The National Institutes of Health's budget, adjusted for inflation, is smaller now than it was in 2003. Universities responded by cutting their own research budgets and leaning hard on industry partnerships. A professor who wants to run a study now often needs corporate sponsorship to cover the costs. This gives pharmaceutical companies enormous power over which diseases get studied, which treatments get compared, and which side effects get highlighted. Research into cheap generic drugs or prevention strategies? Companies won't fund it. Research into expensive new pills? They fund it generously.
The bias extends beyond the numbers. Companies design studies to make their drugs look good. They run their medication against placebos rather than against competing treatments. They choose patient populations most likely to benefit. They measure outcomes that favor their product. Regulators know this happens, and yet they rely almost entirely on industry-funded studies to decide whether to approve new drugs. The fox watches the henhouse, and everyone pretends this is normal.
Some countries have tried to break the cycle. The British National Health Service funds its own research network. Germany and Scandinavia have stronger public research budgets. But these remain exceptions. In the United States and much of the English-speaking world, the pharmaceutical industry now runs medical science. Doctors practice medicine based on research they did not fund and did not design. Patients take drugs approved based on evidence shaped by corporate interests. The system works well for companies. For everyone else, the question remains unanswered: what would we learn if we actually studied these drugs independently?
Published December 17, 2025 · Frisian News · Ljouwert, Fryslân